Tags

Type your tag names separated by a space and hit enter

[Generation of genetic engineering anti-idiotypic antibody against OC125 monoclonal antibody of ovarian carcinoma].
Zhonghua Fu Chan Ke Za Zhi. 1996 Nov; 31(11):646-8.ZF

Abstract

OBJECTIVES

To amplify and express the variable region genes of murine derived anti-idiotypic monoclonal antibody and to develop a new kind of ovarian carcinoma vaccine.

METHODS

mRNA was prepared from murine hybridoma which produces anti-idiotypic antibody against OC125. The heavy and light chain variable region genes (VH and VL) were amplified by polymerase chain reaction (PCR), joined by DNA linker fragments to form single chain FV gene (ScFv), and were ligated into phage mid vector, pCANTAB 5E. The recombinant vector was induced into competent E. coli TG1 cells. The phage displayed recombinant antibodies were detected and identified by enzyme-linked immunosorbent assay (ELISA).

RESULTS

The VH, VL and ScFv genes were 340 bp, 325 bp and 750 bp respectively. Some of the transformed clones expressed engineered anti-idiotypic antibodies, which could specifically bind to the original antibody (OC125).

CONCLUSIONS

Genetic engineering anti-idiotypic antibody against OC125 monoclonal antibody was successfully generated. Clinical application of anti-idiotypic antibody to immunotherapy and to prevention of ovarian carcinoma may be studied.

Authors+Show Affiliations

Gynecological Oncology Center, People's Hospital, Beijing Medical University.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

chi

PubMed ID

9387521

Citation

Zhang, X, et al. "[Generation of Genetic Engineering Anti-idiotypic Antibody Against OC125 Monoclonal Antibody of Ovarian Carcinoma]." Zhonghua Fu Chan Ke Za Zhi, vol. 31, no. 11, 1996, pp. 646-8.
Zhang X, Cui H, Qian H. [Generation of genetic engineering anti-idiotypic antibody against OC125 monoclonal antibody of ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 1996;31(11):646-8.
Zhang, X., Cui, H., & Qian, H. (1996). [Generation of genetic engineering anti-idiotypic antibody against OC125 monoclonal antibody of ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi, 31(11), 646-8.
Zhang X, Cui H, Qian H. [Generation of Genetic Engineering Anti-idiotypic Antibody Against OC125 Monoclonal Antibody of Ovarian Carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 1996;31(11):646-8. PubMed PMID: 9387521.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Generation of genetic engineering anti-idiotypic antibody against OC125 monoclonal antibody of ovarian carcinoma]. AU - Zhang,X, AU - Cui,H, AU - Qian,H, PY - 1996/11/1/pubmed PY - 1997/12/5/medline PY - 1996/11/1/entrez SP - 646 EP - 8 JF - Zhonghua fu chan ke za zhi JO - Zhonghua Fu Chan Ke Za Zhi VL - 31 IS - 11 N2 - OBJECTIVES: To amplify and express the variable region genes of murine derived anti-idiotypic monoclonal antibody and to develop a new kind of ovarian carcinoma vaccine. METHODS: mRNA was prepared from murine hybridoma which produces anti-idiotypic antibody against OC125. The heavy and light chain variable region genes (VH and VL) were amplified by polymerase chain reaction (PCR), joined by DNA linker fragments to form single chain FV gene (ScFv), and were ligated into phage mid vector, pCANTAB 5E. The recombinant vector was induced into competent E. coli TG1 cells. The phage displayed recombinant antibodies were detected and identified by enzyme-linked immunosorbent assay (ELISA). RESULTS: The VH, VL and ScFv genes were 340 bp, 325 bp and 750 bp respectively. Some of the transformed clones expressed engineered anti-idiotypic antibodies, which could specifically bind to the original antibody (OC125). CONCLUSIONS: Genetic engineering anti-idiotypic antibody against OC125 monoclonal antibody was successfully generated. Clinical application of anti-idiotypic antibody to immunotherapy and to prevention of ovarian carcinoma may be studied. SN - 0529-567X UR - https://www.unboundmedicine.com/medline/citation/9387521/[Generation_of_genetic_engineering_anti_idiotypic_antibody_against_OC125_monoclonal_antibody_of_ovarian_carcinoma]_ L2 - https://medlineplus.gov/ovariancancer.html DB - PRIME DP - Unbound Medicine ER -